z-logo
open-access-imgOpen Access
Efficacy of 5‐Day Continuous Lidocaine Infusion for the Treatment of Refractory Complex Regional Pain Syndrome
Author(s) -
Schwartzman Robert J.,
Patel Mona,
Grothusen John R.,
Alexander Guillermo M.
Publication year - 2009
Publication title -
pain medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.893
H-Index - 97
eISSN - 1526-4637
pISSN - 1526-2375
DOI - 10.1111/j.1526-4637.2009.00573.x
Subject(s) - medicine , complex regional pain syndrome , lidocaine , anesthesia , refractory (planetary science) , allodynia , adverse effect , intravenous regional anesthesia , surgery , hyperalgesia , nociception , physics , receptor , astrobiology
Objective.  Chronic regional pain syndrome (CRPS) is a severe pain condition that usually results from an injury or surgical procedure. The pain in CRPS often spreads from the site of injury, and with time becomes refractory to conventional therapy. The present study was undertaken to evaluate the effects of 5‐day continuous intravenous lidocaine treatment in patients afflicted with CRPS. Methods.  Intravenous lidocaine was administered in an escalating dose schedule to 49 severely affected CRPS patients in a monitored setting over 5 days. Evaluation of pain parameters and other signs and symptoms of CRPS were obtained during the infusion and at 1, 3, and 6 months following therapy. Results.  The majority of patients demonstrated a significant decrease in pain parameters and other symptoms and signs of CRPS. The pain reduction lasted an average of 3 months. Lidocaine may be particularly effective for thermal and mechanical allodynia. Less clinically significant effects were documented on the motor aspects of the syndrome. Discussion.  Intravenous lidocaine administration titrated to 5 mg/L demonstrated: 1) a significant decrease in mechanical and thermal allodynia for three months, 2) lessened associated inflammatory components of CRPS, and 3) only minimal side effects and no severe complications.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here